All of our human clinical trials to date for our preventive HIV vaccine candidates have been conducted by the HIV Vaccine Trials Network (HVTN) and funded by National Institutes of Health (NIH). The clinical trial support from the NIH has been provided directly to the HVTN for the conduct of our clinical trials. Our responsibility for these clinical trials has been to provide sufficient supplies of vaccine materials, regulatory and technical expertise when necessary. We expect continued support from the NIH and HVTN for the conduct of future clinical trials.
In addition to clinical trial support from the NIH, our research and development activities have been partially funded by NIH research grants. In total, since the Company's formation in 2001, we have been awarded more than $26 million in NIH grants. The NIH continues to be supportive of our vaccine research programs; we have active grants and intend to seek additional grant funding in the future.